RNS Number : 0530V
Optos plc
22 May 2008
OPTOS PLC
("Optos" or the "Company" or the "Group")
ANALYST AND INVESTOR INFORMATION UPDATE
LONDON, UK, 22 May 2008 - Optos plc (LSE: OPTS), a leading medical technology company for
the design, development, manufacturing and
marketing of retinal imaging devices, is today hosting an analyst and investor information
update in London.
The update follows the announcement yesterday of the Company's interim results, for the
six month period ended 31 March 2008, and will
feature presentations by:
* Jerome Sherman, OD, Eye Institute and Laser Center: New York, NY
* Steven Schwartz, MD, Professor of ophthalmology and Chief of the Retina Division,
Jules Stein Eye Institute, University of
California at Los Angeles (UCLA)
David J. Cairns, Optos' Chief Technical Officer, who will provide an update on the
Company's progress in advanced clinical
applications.
No material price sensitive information will be disclosed and no information relating to
current trading will be provided during the
meeting.
Enquiries
Optos plc +44 (0)1383 843 337
John McNeil, Company Secretary
Maitland +44 (0)20 7379 5151
Anne Wheeler
Neil Bennett
About Optos Plc
Optos plc is a leading and rapidly growing medical technology company for the design,
development, manufacturing and marketing of
devices that image the retina, the light-sensitive area at the back of the eye. Optos has
commercialised a full range of complementary
retinal imaging devices that support different customer segments and patient levels within the
eye and healthcare market: P200 is
concentrated on wellness screening carried out by optometrists and ophthalmologists; P200C in
the advanced clinical optometry and
ophthalmology markets; P200MA supports doctors through an advanced medical angiography
procedure. All three devices provide practitioners
with the benefit of an ultra wide-field high resolution view of the retina, facilitating the
early detection, management and treatment of
disorders and diseases evidenced in the retina such as glaucoma, diabetic retinopathy and
age-related macular degeneration. Retinal imaging
can also indicate evidence of non-eye or systemic diseases such as diabetes, hypertension and
certain cancers. Optos' technology provides an unequalled combination of wide-field retinal
imaging, speed and convenience
for both practitioner and patient and can help save sight and save lives.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These
forward-looking statements are not historical facts
but rather are based on the Company's current expectations, estimates and projections about
its industry, its beliefs and assumptions. Words
such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and
similar expressions are intended to identify
forward-looking statements. These statements are not guarantees of future performance and are
subject to known and unknown risks,
uncertainties and other factors, some of which are beyond the Company's control, are difficult
to predict and could cause actual results to
differ materially from those expressed or forecasted in the forward-looking statements. The
Company cautions shareholders and prospective
shareholders not to place undue reliance on these forward-looking statements, which reflect
the view of the Company only as of the date of
this announcement. The forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company will not undertake any
obligation to
release publicly any revisions or updates to these forward-looking statements to reflect
events, circumstances or unanticipated events
occurring after the date of this announcement except as required by law or by any appropriate
regulatory authority.
news service from the London Stock Exchange
END
MSCGIGDURXDGGID
|